NCT03223194View on ClinicalTrials.gov

Gene Transfer Clinical Study in Crigler-Najjar Syndrome

PHASE1TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

September 8, 2017

Primary Completion Date

February 11, 2021

Study Completion Date

February 11, 2021

Conditions
Crigler-Najjar Syndrome
Interventions
GENETIC

AT342

AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.

Trial Locations (4)

10467

Children's Hospital at Montefiore, The Bronx

17579

Clinic for Special Children, Strasburg

9103102

Shaare Zedek Medical Center, Jerusalem

SE9 9RS

King's College Hospital NHS Foundation Trust, London

Sponsors
All Listed Sponsors
lead

Audentes Therapeutics

INDUSTRY

NCT03223194 - Gene Transfer Clinical Study in Crigler-Najjar Syndrome | Biotech Hunter | Biotech Hunter